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Abstract
Clostridium difficile has been historically viewed as a hospital acquired infection. However, the
emergence of community acquired infection in low risk populations, the identification of new
risk factors, detection of a hypervirulent strain of C. difficile, and increasing mortality have
changed the epidemiology if this infection. Current standards of treatment have come into
question due to increasing recurrence rates and treatment failures, possible resistance of
Metronidazole, and concerns surrounding Vancomycin resistant enterococci (VRE). Fidaxomicin,
a narrow-spectrum macrolide, is the first drug approved by the FDA in 20 years for the
treatment of C. difficile infection. It has shown good in vitro and in vivo activity, has similar
clinical cure rates, lower recurrence rates, and higher global cure rates compared to
Vancomycin in non-hypervirulent strains and similar efficacy in all outcomes in the
hypervirulent strain. Overall, Fidaxomicin appears to be a reasonable second line treatment
option for recurrent C. difficile infection in patients who have failed to respond to treatment
under the current guidelines.
Keywords: Clostridium difficile, Fidaxomicin, Vancomycin
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Introduction
Clostridium difficile (C. difficile), an opportunistic gram positive, anaerobic, sporeforming bacillus, is the most widely recognized cause of infectious diarrhea with a high
healthcare cost burden (McFarland, 2008). There are two primary virulence factors found in C.
difficile infections, toxin A and toxin B (Warny, et al., 2005). These toxins bind to surface
proteins in the intestinal epithelial cells and disrupt the cytoskeleton resulting in a rounding of
the cell, opening of the tight junction between cells and a subsequent fluid release resulting in
diarrhea (McFarland, 2008; Noren, 2010). Toxin A is unique in that it also induces apoptosis of
the cells (McFarland, 2008). Depending on the virulence of the toxin and the host response, C.
difficile can cause a wide array of symptoms ranging from mild, watery diarrhea to life
threatening conditions including: fulminant pseudomembranous colitis, toxic mega colon,
bowel perforation, septic shock and death (LoVecchio & Zacur, 2011; McFarland, 2008). Higher
incidence rates, changing epidemiology, the emerging hypervirulent strain and apparent
decreased efficacy of current treatment options have piqued much interest into the cause and
transmission of C. difficile as well as renewed interest in the pursuit of new treatments for this
disease.
Incidence of C. difficile
The rates of C. difficile have been climbing in the last 15 years with a dramatic rise in
mortality. The CDC reports an eight-fold increase in the number of deaths due to C. difficile
from 1999 to 2006 (Xu, Kochanek, Murphy & Tejada-Vera, 2010). In 2006, C. difficile was added
to the rankable causes of death and is listed as one of the 20 leading causes of death for the
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elderly accounting for nearly 92% of all deaths from C. difficile (Xu, Kochanek, Murphy &
Tejada-Vera, 2010). This is in part due to the changing epidemiology of C. difficile infection.
Historically, the populations at greatest risk for contracting C. difficile have been those
with traditional risk factors which include: previous antibiotic exposure, advanced age, comorbid conditions, feeding tubes, immune suppression/compromise, previous episode of C.
difficile infection, mucosal damage from chemotherapy or radiation, and hospitalizations
(LoVecchio & Zacur, 2011; Freeman, et al., 2010; Noren, 2010). However, there have been
increasing reports of C. difficile in atypical populations. Multiple reports have described a
growing number of C. difficile infections emerging in the community in persons without the
classic risk factors, including recent exposure to antibiotics, which have been implicated in the
acquisition of this infection in children, peripartum women and young adults (Khanna, Pardi,
Aronson, Kammer & Baddour, 2012; Kuntz, Chrischilles, Pendergast, Herwaldt & Polgreen,
2011; McFarland, 2008). It has been postulated that shorter inpatient lengths of stay have led
to community identification of nosocomial infections (Prabaker & Weinstein, 2011).
Hypervirulent Strain
Complicating the epidemiology of this disease is the emergence of a hypervirulent strain
of C. difficile, B1/NAP1/027 (McFarland, 2008). This hypervirulent strain has been implicated in
multiple epidemic outbreaks in Canada and the United States since 1999. The B1/NAP1/027
strain can produce 16 times more toxin A and 23 time more toxin B than non-epidemic strains,
is resistant to fluoroquinolones, and has higher morbidity and mortality rates than nonepidemic strains (LoVecchio & Zacur, 2012; McFarland, 2008; Warny, et al., 2005). To date, this

4

FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM
DIFFICLE INFECTION
hypervirulent strain of C. difficile has been identified in 40 states in the U.S. as well as epidemic
outbreaks in countries globally (Freeman, et al., 2010; Gerding, 2010).
Risk Factors
Exposure to high risk antibiotics remains the primary risk factor for C. difficile
acquisition. Historically, the antibiotic most strongly implicated in the induction of C. difficile
infection was clindamycin (Freeman, et al., 2010). However, more recently many other
antibiotics have come into favor as the cause for C. difficile as the use or misuse of these
medications continues to rise. All antibiotics have the potential to interrupt the normal flora of
the bowel thereby altering the effectiveness of competitive exclusion and increasing the
susceptibility of patients to C. difficile contraction (LoVecchio & Zacur, 2012; McFarland, 2008).
Preservation of the normal flora, mainly comprised of the Clostridium and Bacteroides groups
as well as Lactobacillus, and Bifidobacterium is important to maintain competitive exclusion
(Noren, 2010). The fluoroquinolones specifically have been attributed to the increasing rates of
C. difficile (Freeman, et al., 2010; McFarland, 2008; Noren, 2010).
In addition to antibiotic exposure, several other risk factors have been identified
including age (>65), compromised immune system and comorbid conditions (Freeman, et al.,
2010; LoVecchio & Zacur, 2012; McFarland, 2008). The number of hospitalizations and lengths
of stay have also been identified as contributing risk factors (Freeman, et al, 2010; McFarland,
2008). More recently new sources of susceptibility for C. difficile have been described including
animals and food, the use of feeding tubes, and the use of proton pump inhibitors, the latter of
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which remains highly controversial (Freeman, et al, 2010; Gerding, 2010; LoVecchio & Zacur,
2012; McFarland, 2008; Noren, 2010).
Current Standards of Treatment
LoVecchio & Zacur (2011) describe the properties that pharmacologic therapy for C.
difficile should possess including: oral administration ability, high activity levels in the colon, low
systemic absorption and preservation of normal flora in the colon. Current guidelines call for
discontinuing the offending agent and instituting antimicrobial therapy with oral Metronidazole
or Vancomycin (Cohen, et al., 2010). These are the only two drugs recommended for therapy
but Metronidazole has high systemic absorption with low fecal concentration whereas
Vancomycin has poor systemic absorption and high levels of fecal concentration (Cohen, et al.,
2010).
According to the Infectious Diseases Society of America (IDSA) guidelines,
Metronidazole is the first line treatment for mild-moderate disease but is not approved by the
Food and Drug Administration (FDA) for use in C. difficile and its efficacy appears to be declining
(Cohen, et al., 2010; McFarland, 2008; Miller, 2010). Interestingly, Metronidazole has also been
given a specific black box warning stating “Unnecessary use of the dug should be avoided. Its
use should be reserved only for conditions for which it is approved” (FDA, 2010). For first
recurrence of infection, repeating treatment with the initial choice of drug is recommended.
However, if Metronidazole fails, is poorly tolerated, or contraindicated, second line treatment is
Vancomycin (Cohen, et al., 2010). Repeated recurrences call for use of Vancomycin only in
tapered or pulse dosing as Metronidazole has the “potential for cumulative neurotoxicity”
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(Cohen, et al., 2010, p. 433). However, even with Vancomycin high rates of failure and
recurrence have been described which may be, in part, due to colonization with VRE and the
emergence of B1/NAP1/027 (Choi, et al., 2011; LoVecchio & Zacur, 2012; Prabaker & Weinstein,
2011; Tannock, et al., 2010).
Metronidazole is more cost-effective but has a higher systemic absorption than
Vancomycin which may be the reason for treatment failures with this therapy. Others have
suggested that C. difficile has become resistant to therapy with Metronidazole (Freeman, et al.,
2010; McFarland, 2008; Miller, 2010). However, recurrence rates ranging from 5-47% have
been described with current treatment options (Choi, et al., 2011; LoVecchio & Zacur, 2012;
McFarland, 2008). Current standards of treatment have come into question due to the high
rates of treatment failure and recurrence.
The rates of recurrence and treatment failures, increasing morbidity and mortality,
systemic absorption, few treatment options and emergence of the hyper virulent strain have
raised concern regarding the current treatment options. Optimer Pharmaceuticals has recently
received FDA approval for Fidaxomicin, a narrow spectrum macrocyclic antibiotic, for the
treatment of mild to moderate C. difficile infections and is the first drug to be approved for use
in C. difficile in 25 years (Peterson, 2011). The aim of this study is to review the available
evidence to determine whether fidaxomicin for the treatment of mild to moderate clostridium
difficile infection improves cure rates and decreases the episodes of recurrence as compared to
vancomycin.
Fidaxomicin Versus Current Standard of Treatment
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Pharmacokinetics
Minimum inhibitory concentrations (MIC) are crucial in determining the efficacy of a
medication. A low MIC indicates the lowest concentration of a drug that will inhibit the growth
of the bacteria in question. In the case of C. difficile infection, the MIC against both C. difficile
and the normal bacterial flora become important to understand as preservation of the normal
flora is an important component of efficacious treatment.
In 2004, two quasi-experimental studies were published assessing the in vitro activity of
Fidaxomicin (formerly known as OPT-80) against several hundred anaerobic intestinal bacteria.
MICs were measured in both of these studies and compared to multiple other antibacterial
agents including Vancomycin and Metronidazole. Table 1 summarizes the findings of
Fidaxomicin, Vancomycin, and Metronidazole against C. difficile, all clostridium species,
bacteroides fragilis, lactobacillus and bifidobacteria. Both studies showed good activity for
Fidaxomicin, Vancomycin, and Metronidazole against Clostridium species but with varying MIC
ranges between studies (Credito & Appelbaum, 2004; Finegold, et al., 2004). Superior activity of
Fidaxomicin against C. difficile was shown in both studies. Credito & Appelbaum (2004) found
that Fidaxomicin had superior activity against C. difficile and all clostridium species versus
Vancomycin and Metronidazole, was equivalently active against lactobacillus, bifidobacteria,
and had less activity against bacteroides fragilis than the two current recommended
medications. This would presumably result in higher preservation of normal gut flora in vivo.
In contrast, Finegold, et al. (2004) found that Fidaxomicin was only superior to
Vancomycin in certain clostridium species, specifically clostridial clusters I and XI (including C.
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difficile), had more activity against lactobacillus and bifidobacteria than Metronidazole but not
Vancomycin, and markedly less activity against the bacteroides group and clostridial clusters
XIVa, XI, and XIII than either Vancomycin or Metronidazole. Of note is the variation in the MICs
reported between studies. Finegold, et al. (2004) used a Wadsworth agar dilution technique
whereas Credito & Appelbaum (2004) used a Brucella agar with sheep blood. This difference in
technique may account for the variation in MIC results. However, the results of both studies
support the narrow-spectrum activity of Fidaxomicin which is a desirable trait for antimicrobial
therapy for C. difficile.
The in vivo efficacy of Fidaxomicin was evaluated in two small open-label Phase 2A
randomized dose-finding trials in which authors tested fecal samples of patients for spared
normal bacterial flora after treatment with Fidaxomicin versus Vancomycin. The return of
normal flora, specifically clostridial clusters XIVa and IV, increased during and after treatment
with Fidaxomicin but was not statistically significant (p>0.05), whereas Vancomycin reduced the
population of these clusters as well as bifidobacteria with statistical significance (p<0.05)
(Tannock et al., 2010). This study also reported a statistically significant increase in lactobacilli
and enterococci in the Vancomycin treatment group (p<0.05) which was “coincident with the
decrease in proportions of clostridial clusters and bifidobacteria” (Tannock, et al., 2010, p.
3357). In another study, Fidaxomicin was reported to suppress C. difficile (no p-value given)
and lower recurrence (p=0.03) when compared to Vancomycin with no alteration in bacteroides
(p=0.11-0.56) (Louie, et al., 2009). While the latter outcome was not statistically significant, in
the Vancomycin treatment group alteration in bacteroides was significant (p=0.03) (Louie, et al.,
2009).
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In an additional Phase 2, dose-finding, randomized, open-label study by Louie, et al.
(2009), plasma and fecal levels of Fidaxomicin were measured to assess systemic absorption
and colonic retention of the drug. Plasma levels were found to be less than 20ng/ml in all
subjects receiving the 200mg twice daily dosing and a high fecal concentration of 1433 ± 975
μg/ml (Louie, et al., 2009). These results were supported in their Phase 3 clinical trial which
showed mean plasma concentrations of 22.8 ± 26.5 ng/ml and mean fecal concentrations of
1225 ± 759.0 μg/g (Louie, et al., 2011). These studies did not compare Fidaxomicin levels
against Vancomycin levels. While no statistical significance was reported, this is clinically
significant as effective treatment for C. difficile must have low systemic absorption and high
fecal concentrations to be effective.
Clinical cure and recurrence
Clinical efficacy of Fidaxomicin versus Vancomycin was reported in three studies, two
large randomized control trials and a systematic review. Initial clinical cure, recurrence and
global cure were reported in both trials. Global cure was not reported in the systematic review.
The studies are summarized in Table 2 with demographics and interventions outlined in Table 3.
Clinical cure.
Clinical cure was defined by the authors as resolution of diarrhea which is maintained
until 2 days after treatment completion (Louie, et al., 2011; Mullane, et al., 2011). Fidaxomicin
clinical cure rates were found to be non-inferior to Vancomycin in all three studies. Drekonja, et
al. (2011) reported no significant difference between Fidaxomicin and Vancomycin, giving no pvalue. When given with a concomitant antibiotic, Fidaxomicin was found to have higher clinical
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cure than Vancomycin (p=0.04) but the clinical cure rate in the presence of high-risk
concomitant antibiotics did not reveal a statistical significance (p=0.09) (Mullane, et al., 2011).
One study reported clinical cure rates in Fidaxomicin for the modified intention to treat (mITT)
and per protocol (PP) groups as non-inferior to Vancomycin “with a lower boundary of the
97.5% CI for the difference in cure rates of -3.1…[and] -2.6 percentage points” respectively
(Louie et al., 2011).
Recurrence.
Recurrence rates were reported by all three studies. Clinical recurrence was defined in
the randomized control trials as the reappearance of symptoms (more than three unformed
stools per day) within 4 weeks after completion of therapy, C. difficile toxin A or B, or both in
stool, and treatment requirement for infection (Louie, et al., 2011; Mullane, et al., 2011). Louie,
et al. (2011) reports statistically significant lower recurrence rates with Fidaxomicin in both the
mITT group (p=0.005) and the PP group (p=0.004). This study did show similar rates of
recurrence between Fidaxomicin and Vancomycin on the B1/NAP1/027 hyper virulent strain
which was not statistically significant (p=0.93) (Louie, et al., 2011). Administration of
Fidaxomicin with concomitant antibiotics, was found to have increased recurrence rates but it
did not reach statistical significance (p=0.48) and in conjunction with high risk antibiotics the
difference in rate of recurrence between Fidaxomicin and Vancomycin was not statistically
significant (p=0.54) (Mullane, et al., 2011). In a systematic review, Drekonja, et al. (2011) found
that the overall recurrence rate for Fidaxomicin was lower than Vancomycin (p=0.005).
Global Cure.
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Global cure is defined as “clinical cure with no recurrence” (Mullane, et al, 2011). Two
studies reported results for global cure. Louie, et al. (2011) reports a statistically significant
global cure rate for Fidaxomicin in both the mITT and PP groups with p=0.006 for both groups.
In a study evaluating cure rates with concomitant antibiotic use, global cure rate was
statistically significant (p=0.02) except when adjunctive high risk antibiotics were used (p=0.18)
(Mullane, et al., 2011).
Strengths/Limitations
The studies conducted by Louie, et al. (2011) and Mullane, et al. (2011) were both
double-blind randomized control trials. This approach has strong rigor, lends itself to
generalizability and has strong external validity due to the “natural” setting. The remaining
studies were quasi-experimental with quite small samples sizes which weakens the
generalizability and external validity of these studies. Additionally, no study reported power
analysis or effect size which further weakens their external validity. The results of these studies
must be interpreted with caution. Bias is a major concern with each of the studies evaluated as
it was either funded by Optimer pharmaceuticals, the manufacturer of Fidaxomicin, or written
by an investigator employed by said manufacturer. The systematic review provides the
strongest form of evidence and lessens the bias that may be present in the other studies.
Discussion
Fidaxomicin is the first antibiotic to be approved by the FDA for treatment of C. difficile
in 20 years. It has good in vitro and in vivo efficacy, has been shown to be non-inferior to Vanco
in clinical trials, in both epidemic and non-epidemic strains, and appears to significantly
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decrease the rate of recurrent infection. Additionally, it meets the criteria for effective
treatment of C. difficile: It is given orally, has low systemic absorption, high fecal concentrations
and preserves the normal bacterial flora of the bowel, which the current treatments do not.
Fidaxomicin appears to be a reasonable alternative therapy for recurrent C. difficile but
not for initial treatment. As the only randomized control studies that have been published were
conducted by Optimer Pharmaceuticals, bias is a concern. Large, independent trials are
warranted to provide a clearer picture of its overall efficacy against C. difficile and superiority in
treatment versus Vancomycin.
Additionally, pharmacoeconomics cannot be disregarded when choosing therapy. In a
review of this new drug, Grant (2011) reports wholesale pricing of Fidaxomicin much higher
than Vancomycin for a 10-day course of treatment ($2,800 versus $1,061 respectively). Retail
pricing shows Fidaxomicin is $3,260.19 for a 10-day course as opposed to Vanco which is $1,365
and Metronidazole is markedly less expensive than either of these drugs at $27 for a 10-day
course (N. Bidinger, personal communication, April 2, 2011). It may be reasonable to offset the
concern of cost with decreased recurrence rates in those patients who experience recurrent
infection. However, this will prohibit many providers from prescribing and will not be covered
under health insurance plans requiring, at minimum, a pre-authorization for coverage.
For health care providers, prudent prescription of antimicrobial agents is of utmost
importance in preventing the contraction of C. difficile. If a high-risk antimicrobial must be used,
such as Clindamycin or a flouroquinolone, signs and symptoms of C. difficile should be included
in the counseling of patient, such as more than three watery stools a day, abdominal cramping,
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fever, nausea, and dehydration so the offending agent can be discontinued and treatment for
the infection can be instituted early (Mayo Clinic, 2010).
Polymerase chain reaction (PCR) testing is generally used to assess the presence of C.
difficile in stool. This test is rapid, with high sensitivity and specificity (Cohen, et al., 2010).
However, current guidelines report that more data is still needed on PCR testing before an
official recommendation will be issued for use of PCR (Cohen, et al., 2010). Rather, guidelines
state that identification of the infection should be obtained using an enzyme immunoassay test
(EIA) to screen followed by a toxinogenic culture for confirmation (Cohen, et al., 2010). The
IDSA guidelines support this method as an “interim recommendation” pending more data on
sensitivity and support stool culture as the gold standard but acknowledge that “stool culture is
not clinically practical because of its slow turnaround time” (Cohen, et al., 2010, p.9).
If recurrent C. difficile is diagnosed with failed response to current treatment guidelines,
Fidaxomicin is a reasonable next line therapy. Patients should be counseled on duration of
treatment (10 days of twice daily dosing), side effects of the medication including abdominal
pain, nausea and vomiting, anemia, and neutropenia, as well as the more serious side effects of
bowel obstruction and gastrointestinal hemorrhage (FDA, 2011). Follow-up should occur after
therapy and with any progression of disease symptoms, non-resolution of symptoms, and
recurrence of infection.
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Table 1. In vitro activity of Fidaxomicin, Vancomycin and Metronidazole against select bacterial isolates
Study

Bacterial group

Antimicrobial agent

MIC50

MIC90

Finegold, et al (2004)

C. difficile

Fidaxomicin
Vancomycin
Metronidazole

0.12
1
0.25

0.25
2
0.5

0.062
1
≤0.5

128
16
1.0

Fidaxomicin
Vancomycin
Metronidazole

1
1
4.0

32.0
2
>128

Fidaxomicin
Vancomycin
Metronidazole

256
64
1

1024
128
4

Fidaxomicin
Vancomycin
Metronidazole

≤0.016
0.5
≤0.125

0.25
2.0
0.5

All clostridium species Fidaxomicin
Vancomycin
Metronidazole

≤0.016
0.25
≤0.125

0.25
2.0
2.0

Fidaxomicin
Vancomycin
Metronidazole

0.25
0.25
2.0

16.0
16.0
>16.0

Fidaxomicin
Vancomycin
Metronidazole

64.0
>16.0
0.25

>128
>16.0
1.0

All clostridium species Fidaxomicin
Vancomycin
Metronidazole
Miscellaneous gram-positive
non-spore-forming rods
Includes lactobacillus and
bifidobacteria
Bacteroides fragilis

Credito, et al (2004)

C. difficile

Miscellaneous gram-positive
non-spore-forming rods
Includes lactobacillus and
bifidobacteria
Bacteroides fragilis

MIC50 - MIC at which 50% of isolates tested were inhibited
MIC90 – MIC at which 90% of isolates tested were inhibited
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Table 2. Efficacy of Fidaxomicin versus Vancomycin in clinical cure rates, recurrence, and global cure
rates
Author

Clinical cure

Recurrence

Global cure

Drekonja, et al (2011)

no significant difference

p=0.005

not reported

Louie, et al (2009)
mITT group
PP group

-3.1 percentage points
-2.6 percentage points

p=0.005
p=0.004

p=0.006
p=0.006

Mullane, et al (2011)
With any CA antibiotic
With high-risk antibiotic

P=0.04
p=0.09

p=0.048
p=0.54

p=0.02
p=0.18

mITT: modified intention to treat group
PP: per protocol group
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Table 3. Demographics and interventions of studies examining the efficacy of Fidaxomicin versus
Vancomycin in clinical cure rates, recurrence, and global cure rates
Author

Purpose

Sample

Drekojna, et
al (2011)

To determine
whether among
adults with C.
Diff, treatment
with certain
antibiotics
compared with
others results in
differences in
initial cure,
recurrence, and
harms
Compare the
efficacy and
safety of
fidaxomicin
with those of
vancomycin in
treating C. Diff
infection

1324 subjects

629 patients
302 fidaxomicin
327 vancomycin
mITT: 596
333 female
263 male
354 inpt
242 outpt
PP: 548
329 female
219 male
308 inpt
240 outpt

Double Blind
RCT

To study the
effects of
concomitant
antibiotics on
response to
fidaxomicin and
vancomycin

999 subjects
584 female
415 male
393 outpatient
606 inpatient
481 fidaxomicin
518 vancomycin
Recurrence:
794 subjects
391 fidaxomicin
403 vancomycin

Double Blind
RCT

Louie, et al
(2011)

Mullane, et al
(2011)

Research
Design
Systematic
Review

Measures
Fecal samples

Intervention
Outcomes
IV: Fidaxomicin
Vancomycin
Flagyl
Other
Antibiotics
DV:
Initial Cure
Recurrence

Fecal samples
for toxin tests

IV:
Fidaxomicin
Vancomycin

Blood samples
for PD effects DV:
Clinical Cure
Recurrence
Global Cure

Fecal samples

IV: Fidaxomicin
Vancomycin
DV:
Clinical cure
Recurrence
Global cure

mITT: modified intention to treat; PP: pre protocol; IV: independent variable; DV: dependent variable
RCT: Randomized control trial
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